Rifampin Pharmacokinetics/Pharmacodynamics in the Hollow-Fiber Model of Mycobacterium kansasii Infection
In: Antimicrobial Agents and Chemotherapy, Jg. 66 (2022-04-19)
Online
unknown
Zugriff:
There is limited high-quality evidence to guide the optimal treatment of Mycobacterium kansasii pulmonary disease. We retrospectively collected clinical data from 33 patients with M. kansasii pulmonary disease to determine the time-to-sputum culture conversion (SCC) upon treatment with a standard combination regimen consist of isoniazid-rifampin-ethambutol. Next, MIC experiments with 20 clinical isolates were performed, followed by a dose-response study with the standard laboratory strain using the hollow-fiber system model of M. kansasii infection (HFS- Mkn ). The inhibitory sigmoid maximum effect ( E max ) model was used to describe the relationship between the bacterial burden and rifampin concentrations.
Titel: |
Rifampin Pharmacokinetics/Pharmacodynamics in the Hollow-Fiber Model of Mycobacterium kansasii Infection
|
---|---|
Autor/in / Beteiligte Person: | Srivastava, Shashikant ; Boorgula, Gunavanthi D. ; Wang, Jann-Yuan ; Huang, Hung-Ling ; Howe, Dave ; Gumbo, Tawanda ; Heysell, Scott K. |
Link: | |
Zeitschrift: | Antimicrobial Agents and Chemotherapy, Jg. 66 (2022-04-19) |
Veröffentlichung: | American Society for Microbiology, 2022 |
Medientyp: | unknown |
ISSN: | 1098-6596 (print) ; 0066-4804 (print) |
DOI: | 10.1128/aac.02320-21 |
Schlagwort: |
|
Sonstiges: |
|